发明名称 TETRAHYDRO-BENZODIAZEPINONES
摘要 Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.;
申请公布号 US2016272596(A1) 申请公布日期 2016.09.22
申请号 US201415037240 申请日期 2014.11.14
申请人 HOFFMANN-LA ROCHE AG 发明人 Chen Shaoqing;Donnell Andrew F.;Kester Robert Francis;Le Kang;Lou Yan;Michoud Christophe;Remiszewski Stacy;Rupert Kenneth C.;Weisel Martin
分类号 C07D243/14;C07D403/06;C07D405/06;C07D413/06;C07D401/06;C07D403/12 主分类号 C07D243/14
代理机构 代理人
主权项 1. A compound of formula I′:whereinW and X are the same or different and each is independently selected from the group consisting of H, hydroxyl-C1-6-alkyl, and C1-6-alkyl that optionally includes 1-3 deuterium atoms,or alternatively, W together with the nitrogen to which it is bound and Y together with the carbon to which it is bound can form a C3-9-heterocycle;Y is C1-6-alkylZ is selected from the group consisting of C1-6-alkyl that optionally may be substituted with aryl, aryl that optionally may be substituted with cyano, C1-6-alkyl, C1-6-alkoxy, C3-7-cycloalkyl, OCD3, halo-C16-alkoxy, halo, COO—C1-6-alkyl, COOH or CON(H, C1-6-alkyl), and heteroaryl that optionally may be substituted with C1-6-alkyl, C1-6-alkoxy, C3-7-cycloalkyl, halo-C1-6-alkoxy, halo, COOR9, CONR6R7, oxo or phenyl that optionally may be substituted with cyano, CONR10R11; R1, R2 and R3 are selected from the group consisting of H, CN, halo, and halo-C1-6-alkyl;R4 is selected from the group consisting of H, C1-6-alkyl, and aryl;R5 is selected from the group consisting of H, benzyl, that optionally may be substituted with acetyl, amido, amino, cyano, C1-6-alkyl, C1-6-alkoxy, hydroxy-C1-6-alkyl, halo and nitro, aryl that optionally may be substituted with acetyl, amido, amino, cyano, C1-6-alkyl, C1-6-alkoxy, hydroxy-C1-6-alkyl, halo and nitro, heteroaryl, C1-6-alkyl that optionally may be substituted with aryl that optionally may be substituted with cyano or C1-6-alkoxy, C(O)R6, SO2—CH2—SO2—C1-6-alkyl, SO2—N(C1-6-alkyl)2, SO2—NH2, SO2—N(H,C1-6-alkyl), SO2-aryl that optionally may be substituted with C1-6-alkoxy, nitro, amino, N(H, C(O)—C1-6-alkyl) or C(O)—C1-6-alkyl, SO2—C1-6-alkyl, and COO—C1-6-alkyl, and R5 optionally may be linked with Z to form —C(═O)—(CH2)a—NR12—C(═O)-aryl-CH2—, whereby a is 1, 2, 3 or 4, and the aryl moiety can optionally be substituted by C1-6-alkoxy;R6 is selected from the group consisting of C1-6-alkyl that optionally may be substituted with amino, N(H, C1-6-alkyl), COOH, nitro or C1-6-alkoxy, (CH2)i-aryl that optionally may be substituted with amino, cyano, nitro, halo, SO2—C1-6-alkyl, C(O)—C1-6-alkyl, C(O)—O—C1-6-alkyl, C(O)—OH, C1-6-alkoxy, C(O)—NH2, C(O)—NH—(CH2)j—C3-7-cycloalkyl, N(H, C(O)—C1-6-alkyl), N(H, C(O)—O—C1-6-alkyl-aryl) or C1-6-alkyl that optionally may be substituted with halo and hydroxy, i=0 or 1 and j=0 or 1, (CH2)k-heterocycle that optionally may be substituted with C1-6-alkyl, k=0, 1 or 2, (CH2)l-heteroaryl that optionally may be substituted with C1-6-alkyl, C3-7-cycloalkyl, phenyl or halo, l=0, 1 or 2 and the aryl moiety may optionally be substituted by CN, (CH2)m—O—(CH2)n—O—C1-6-alkyl, m=1 or 2, n=1, 2 or 3, (CH2)o—(C═O)—NR7R8, o=0, 1 or 2, (CH2)p—O—(CH2)q—O—(CH2)r—O—C1-6-alkyl, p=l or 2, q=1, 2 or 3, r=1, 2 or 3, (CH2)s—(C═O)—C1-6-alkyl, s=1, 2 or 3, (CH2)t—(C═O)—O—C1-6-alkyl, t=1, 2, 3 or 4, (CH2)u—C3-7-cycloalkyl, u=1 or 2, (CH2)v—NH—(C═O)—O—(CH2)w-aryl, v=1, 2 or 3, w=1 or 2, and (CH2)x-SO2—C1-6-alkyl, x=1 or 2, N(H, C1-6-alkyl);R7 or R8 each individually selected from the group consisting of H, and C1-6-alkyl;R9 is selected from the group consisting of H,R10 is selected from the group consisting of H,R11 is selected from the group consisting of aryl, and heteroaryl;R12 is selected from the group consisting of H, and C1-6-alkyl;or a pharmaceutically acceptable salt thereof.
地址 Nutley NJ US